Using Mobile Phones to Improve Adherence to Inhaled Steroids

Not Applicable

Completed

• Conditions: Asthma
• Interventions: Behavioral: Asthma Supervision; Behavioral: Mobile Phone; Behavioral: Inhaled Corticosteroid Mobile Phone Application; Behavioral: Beta2-adrenergic agonist Mobile Phone Application

• Registration Number: NCT01710059
• Lead Sponsor: Rush University Medical Center

Brief Summary

This study has two main goals. The first goal is to test whether a mobile phone intervention can increase adherence to daily inhaled steroid medications in African American adolescents prescribed this type of medication by his/her asthma doctor. The second goal is to use a mobile phone intervention to better understand real life patterns of use of quick-relief (beta2-adrenergic agonist) asthma medication in this population.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-10-16
• Study First Submitted QC: 2012-10-16
• Study First Posted: 2012-10-18
• Study Start: 2012-12
• Primary Completion: 2013-11
• Study Completion: 2013-11
• Status Verified: 2014-02
• Last Update Submitted: 2014-02-10
• Last Update Posted: 2014-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• 11-16 years of age
• self-identify as African American
• have persistent asthma
• be on a prescription daily inhaled corticosteroid medication for asthma
• be on a prescription inhaled beta2-adrenergic agonist medication for asthma

Exclusion Criteria

• candidate refusal
• the presence of other co-morbidities that could interfere wtih study participation
• > 60% adherence to inhaled corticosteroid medication, measured by the electronic dose counter, during the run-in period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental: Intervention Group	Inhaled Corticosteroid Mobile Phone Application	Experimental: Intervention Group 1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma.
Experimental: Intervention Group	Beta2-adrenergic agonist Mobile Phone Application	Experimental: Intervention Group 1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma.
Experimental: Intervention Group	Asthma Supervision	Experimental: Intervention Group 1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma.
Experimental: Intervention Group	Mobile Phone	Experimental: Intervention Group 1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma.

Primary Outcome Measures

Name	Time	Method
Adherence to inhaled corticosteroids, measured objectively using an electronic dose counter	10 weeks	Adherence is measured as the mean of daily adherence to prescription inhaled corticosteroid dose over 14 days both at baseline and at week 10 of the active treatment phase. For the primary outcome, we will compare adherence at week 10 to adherence at baseline.

Secondary Outcome Measures

Name	Time	Method
To understand patterns of use of quick-relief medication for asthma	10 weeks	This study will use an electronic dose counter and mobile phone technology to track participants real time use of quick-relief (beta2-adrenergic agonist) medication for asthma during the 10 weeks of active treatment.

Trial Locations

Locations (1)

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States